StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Incyte (INCY) Sell-Off on Opzelura Miss an 'Overreaction' - Truist
August 2, 2022 12:45 PM
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), saying the stock ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Incyte's (INCY) "Opzelura Miss is Likely to Weigh on Shares" - BMO Capital Keeps Stock at Market Perform with $81 Price Target Post Q2 Earnings
August 2, 2022 7:44 AM
Form 8-K INCYTE CORP For: Aug 02
August 2, 2022 7:26 AM
Incyte (INCY) Tops Q2 EPS by 45c
August 2, 2022 7:08 AM
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 2, 2022 7:00 AM
JPMorgan Assumes Incyte (INCY) at Neutral
August 1, 2022 5:03 PM
